127 related articles for article (PubMed ID: 8371582)
1. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes.
Stenke L; Wallvik J; Celsing F; Hast R
Leukemia; 1993 Sep; 7(9):1324-7. PubMed ID: 8371582
[TBL] [Abstract][Full Text] [Related]
2. Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.
Balleari E; Clavio M; Arboscello E; Bellodi A; Bruzzone A; Del Corso L; Lucchetti MV; Miglino M; Passalia C; Pierri I; Ponassi I; Oneto C; Racchi O; Scudeletti M; Vignolo L; Zoppoli G; Gobbi M; Ghio R
Leuk Res; 2011 Nov; 35(11):1472-6. PubMed ID: 21794914
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome.
Stasi R; Brunetti M; Bussa S; Conforti M; Martin LS; La Presa M; Bianchi M; Parma A; Pagano A
Clin Lab Haematol; 1997 Sep; 19(3):197-201. PubMed ID: 9352145
[TBL] [Abstract][Full Text] [Related]
6. Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment.
Yoshida Y; Anzai N; Kawabata H; Kohsaka Y; Okuma M
Ann Hematol; 1993 Apr; 66(4):175-80. PubMed ID: 8485205
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human erythropoietin for treatment of myelodysplastic syndromes.
Rafanelli D; Grossi A; Longo G; Vannucchi AM; Bacci P; Ferrini PR
Leukemia; 1992 Apr; 6(4):323-7. PubMed ID: 1588794
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
[TBL] [Abstract][Full Text] [Related]
9. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
10. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
11. Treatment of MDS patients with recombinant human erythropoietin and the role of GSTs.
Tsabouri SE; Georgiou I; Katsaraki A; Bourantas KL
J Exp Clin Cancer Res; 2004 Sep; 23(3):417-24. PubMed ID: 15595630
[TBL] [Abstract][Full Text] [Related]
12. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin.
Economopoulos T; Mellou S; Papageorgiou E; Pappa V; Kokkinou V; Stathopoulou E; Pappa M; Raptis S
Leukemia; 1999 Jul; 13(7):1009-12. PubMed ID: 10400415
[TBL] [Abstract][Full Text] [Related]
13. Characterization of circulating erythrocytes from myelodysplastic patients treated with recombinant human erythropoietin.
Shapiro S; Gershon H; Rosenbaum H; Merchav S
Leukemia; 1993 Sep; 7(9):1328-33. PubMed ID: 8371583
[TBL] [Abstract][Full Text] [Related]
14. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes.
Stasi R; Brunetti M; Bussa S; Conforti M; Di Giulio C; Crescenzi A; Terzoli E; Vecchione A; Pagano A
Clin Cancer Res; 1997 May; 3(5):733-9. PubMed ID: 9815743
[TBL] [Abstract][Full Text] [Related]
15. Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant human erythropoietin in myelodysplastic syndromes.
Depaoli L; Levis A; Isabella N; Ficara F; Priotto C; Lista P; Foà R; Resegotti L
Haematologica; 1993; 78(2):118-22. PubMed ID: 8349187
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human erythropoietin in patients with myelodysplastic syndromes.
Schouten HC; Vellenga E; van Rhenen DJ; de Wolf JT; Coppens PJ; Blijham GH
Leukemia; 1991 May; 5(5):432-6. PubMed ID: 2033964
[TBL] [Abstract][Full Text] [Related]
17. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide for the treatment of patients with myelodysplastic syndromes.
Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N
Leukemia; 2002 Jan; 16(1):1-6. PubMed ID: 11840256
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes.
Ghio R; Balleari E; Ballestrero A; Gatti AM; Mareni C; Massa G; Patrone F; Sessarego M; Timitilli S
Acta Haematol; 1993; 90(2):58-64. PubMed ID: 8285019
[TBL] [Abstract][Full Text] [Related]
20. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes.
Wallvik J; Stenke L; Bernell P; Nordahl G; Hippe E; Hast R
Eur J Haematol; 2002 Mar; 68(3):180-5. PubMed ID: 12068800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]